Sponsored

Chimeric (ASX:CHM) gets patent in India and notice of acceptance in Israel - Kalkine Media

May 01, 2023 10:56 AM AEST | By Ankit Sethi
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Chimeric is developing a range of cell therapies including CHM 1101, CHM 2101 and others for treatment of cancer
  • The company has been granted patent in India spanning its therapies CHM 1101 and CHM 1301
  • The Israel Patent Office has issued a notice of allowance for Chimeric's application IL 258670

Chimeric Therapeutics (ASX: CHM) -- an Australian-based listed entity progressing in the clinical stage cell therapy space -- has informed about the grant of patent in India and a notice of allowance in Israel. The Indian Patent Office has granted Chimeric patent for applications of the chimeric antigen receptor technology using chlorotoxin. This also includes company's CHM 1101, and CHM 1301. The latter is in clinical stage and former is in pre-clinical stage.

CHM's CEO and Managing Director has lauded this recent development and commented that the company would progress with expansion of its intellectual property portfolio that underpins Chimeric's CLTX CAR pipeline assets. CHM shares on ASX traded at AU$0.071 at the time of writing, with a market cap of over AU$31 million.

Data source: CHM ASX announcement dated 28 April 2023; Image source: Pixabay.com

The development

According to CHM’s latest announcement, the patent office of India has granted a patent enabling certain applications of company’s chimeric antigen receptor technology with the use of chlorotoxin. The patent also includes CHM’s two cellular therapies, namely CHM 1101, and CHM 1301. The former is a CAR T asset and is in clinical stage, while the latter is a CAR NK asset and is in pre-clinical stage. The Indian patent comes with number IN 424963.

Separately, the patent office of Israel has also issued an Official Notification Prior to Acceptance. This is for Chimeric’s application IL 258670 and is a notice of allowance for the application. Notably, Chimeric Therapeutics has exclusive worldwide license for development and commercialisation of IN 424963, IL 258670, and related patent applications filed in other international jurisdictions.

About Chimeric Therapeutics

CHM is only clinical stage cell therapy developer listed in Australia on the ASX (under ticker CHM) and is working on therapies for treatment of cancer. The Company asserts that cell therapies not just delay the progression of the disease, but are also capable of curing it.

The Company’s portfolio includes two CAR T therapies, alongside the allogeneic NK cell therapy platform. There are two ongoing clinical programs and Chimeric states it is planning to add more programs this year.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.